Video

Impact of metastases location on mCRPC treatment selection

Author(s):

Urology Times staff

Jingsong Zhang, MD, PhD is a genitourinary oncologist at Moffitt Cancer Center and an assistant professor of oncology and internal medicine at the University of South Florida College of Medicine, discusses how the site of metastases impacts his approach to treatment selection for patients with metastatic castration-resistant prostate cancer.

Related Videos
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
1 expert in this video
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Related Content
Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD
"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke
Initial study results may be available as soon as the first half of 2026.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor
The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
ARANOTE substudy highlights benefits of darolutamide in Black men
April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor
The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
© 2025 MJH Life Sciences

All rights reserved.